Pregnant female undergoing ceaserean section receiving I.V.Tranexamic acid 1g to see its effectiveness in reducing blood loss.

Phase 2/3

Not yet recruiting

• Conditions: Other immediate postpartum hemorrhage,

• Registration Number: CTRI/2025/05/087067
• Lead Sponsor: Dr Venisree

Brief Summary

Tranexamic acid (TXA) has been extensively studied for its efficacy and safety in reducing blood loss during and after caesarean section (CS), a procedure associated with increased risk of postpartum hemorrhage (PPH)Regarding safety, TXA administration was associated with a reduced risk of PPH and transfusions, with no significant increase in thromboembolic events . Minor side effects were more common in the TXA group than in the control group, but these were not clinically significant .In conclusion, prophylactic administration of TXA before caesarean section is an effective and safe intervention to reduce blood loss and associated complications. Its use is particularly advantageous in settings where blood conservation is critical and in patients at higher risk of bleeding.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-05-15
• Study Start: 2025-05-26

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 94

Inclusion Criteria

• pregnant women above 18 years.
• All consenting women undergoing caeserean section.

Exclusion Criteria

• Exclusion criteria Non consenting patients Prior history of Thromboembolism and bleeding disorders Patients on Anticoagulants Acute Fetal Distress •Failed instrumental delivery Exclusion criteria: •Non consenting patients •Prior history of Thromboembolism and bleeding disorders.
• •Patients on Anticoagulants •Acute Fetal Distress •Failed instrumental delivery.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TO COMPARE THE DIFFERENCE IN INTRAOPERATIVE BLOOD LOSS DURING C SECTION AFTER PROPHYLACTIC ADMINISTRATION OF 1G IV TRANEXEMIC ACID	AFTER 10 MINS OF SKIN CLOSURE

Secondary Outcome Measures

Name	Time	Method
TO compare need of additional uterotonics drugs & measures	To compare side effects

Trial Locations

Locations (1)

Aiims jodhpur; 🇮🇳 Jodhpur, RAJASTHAN, India

Aiims jodhpur

🇮🇳Jodhpur, RAJASTHAN, India

Dr Venisree

Principal investigator

7993632492

venisreemudavath12@gmail.com